Linz W, Martorana P A, Schölkens B A
Hoechst AG, Frankfurt, F.R.G.
J Cardiovasc Pharmacol. 1990;15 Suppl 6:S99-109.
Local inhibition of angiotensin-converting enzyme (ACE, kininase II) produces both attenuation of angiotensin (Ang) II generation and bradykinin (BK) degradation. To delineate the participation of BK in the cardioprotective actions of ACE inhibitors, experiments were performed in rats and dogs with cardiac ischemia-reperfusion injuries. (I) In rat isolated perfused working hearts with regional myocardial ischemia, BK in concentrations as low as 1 X 10(-9) M increased coronary flow (CF) and reduced the incidence and duration of reperfusion ventricular fibrillation (VF). In addition, enzyme activities of lactate dehydrogenase (LDH) and creatine kinase as well as lactate output were decreased in the venous effluent of BK-perfused hearts, which also showed improved cardiodynamic and metabolic parameters. Even concentrations of BK lower than 1 X 10(-10) M, which were without influence on coronary flow, exerted comparable beneficial metabolic effects connected with reduced incidence and duration of VF. Combined perfusions with threshold concentrations of BK (1 X 10(-12) M) and the ACE inhibitor ramiprilat (2.58 X 10(-9) M), which were ineffective given alone, resulted in a marked cardioprotective effect. Perfusion with Ang II (1 X 10(-9) M) aggravated reperfusion arrhythmias and worsened myocardial metabolism. BK perfusion prevented this deterioration in a concentration-dependent manner, whereas the Ang II receptor antagonist saralasin was only marginally effective. The BK antagonist D-Arg-[Hyp2, Thi5,8, D-Phe7]-BK (1 X 10(-5) M) completely abolished the cardioprotective effects of BK or the ACE inhibitor. However, higher concentrations of BK (1 X 10(-7) M) or ramiprilat (2.58 X 10(-5) M) competitively reversed these properties of the BK antagonist. (II) In anesthetized dogs, BK was infused into the coronary artery in a dose of 1 ng/kg/min during occlusion (90 min) and reperfusion (30 min) of the left descending coronary artery (LAD)--a dose without effects on cardiovascular parameters. In line with the findings in isolated ischemic rat hearts, BK infusion reduced LDH activities and lactate concentrations in the coronary sinus blood, whereas myocardial tissue levels of glycogen and energy-rich phosphates were increased in the infarcted area. The cardioprotective effects produced by perfusion with BK or by reduction of BK degradation through local interference with ACE favor a role for BK in ischemia-reperfusion injuries in rats and dogs.
局部抑制血管紧张素转换酶(ACE,激肽酶II)可使血管紧张素(Ang)II生成减少以及缓激肽(BK)降解减弱。为了阐明BK在ACE抑制剂心脏保护作用中的参与情况,我们在患有心脏缺血再灌注损伤的大鼠和犬身上进行了实验。(I)在大鼠离体灌注工作心脏并伴有局部心肌缺血的实验中,低至1×10⁻⁹ M浓度的BK可增加冠脉血流量(CF),并降低再灌注室颤(VF)的发生率和持续时间。此外,BK灌注心脏的静脉流出液中乳酸脱氢酶(LDH)和肌酸激酶的酶活性以及乳酸输出量均降低,同时心脏动力学和代谢参数也有所改善。即使是低于1×10⁻¹⁰ M的BK浓度,虽对冠脉血流量无影响,但也产生了与降低VF发生率和持续时间相关的类似有益代谢效应。将阈值浓度的BK(1×10⁻¹² M)与ACE抑制剂雷米普利拉(2.58×10⁻⁹ M)联合灌注,单独使用时二者均无效,但联合灌注却产生了显著的心脏保护作用。用Ang II(1×10⁻⁹ M)灌注会加重再灌注心律失常并使心肌代谢恶化。BK灌注以浓度依赖的方式防止了这种恶化,而Ang II受体拮抗剂沙拉新仅具有微弱的效果。BK拮抗剂D - Arg - [Hyp2, Thi5,8, D - Phe7] - BK(1×10⁻⁵ M)完全消除了BK或ACE抑制剂的心脏保护作用。然而,更高浓度的BK(1×10⁻⁷ M)或雷米普利拉(2.58×10⁻⁵ M)可竞争性逆转BK拮抗剂的这些特性。(II)在麻醉犬中,在左冠状动脉前降支(LAD)闭塞(90分钟)和再灌注(30分钟)期间,以1 ng/kg/min的剂量将BK注入冠状动脉——该剂量对心血管参数无影响。与离体缺血大鼠心脏的研究结果一致,BK注入可降低冠状窦血中的LDH活性和乳酸浓度,而梗死区域心肌组织中的糖原和高能磷酸盐水平则升高。BK灌注或通过局部干扰ACE减少BK降解所产生的心脏保护作用,表明BK在大鼠和犬的缺血再灌注损伤中发挥作用。